Introduction {#sec1-1}
============

Hepatitis C virus (HCV) infection is an important etiological factor of chronic liver disease worldwide, with an estimated of more than 170 million people currently infected with the virus (Lemoine and Thursz, 2014). Most infected individuals develop into chronic hepatitis, which could progress to cirrhosis and the occurrence of hepatocellular carcinoma (HCC) (Intaraprasong et al., 2016). Various viral, host and environmental factors have been influenced the chronicity and disease progression, including male sex, time of HCV infection, obesity, diabetes, alcohol consumption and co-infection with human immunodeficiency (HIV) (Hajarizadeh et al., 2013). In fact, HIV infection could modify the natural history of chronic HCV infection in co-infected patients, with a higher likelihood of fibrosis progression and cirrhosis. For example, our previous data showed that approximately 40% and 25% of HCV/HIV co-infected and HCV mono-infected patients had advanced liver fibrosis (Avihingsanon et al., 2014).

Host genetic variations have been implicated to influence the natural history of chronic HCV infection. Recent studies have shown that several single nucleotide polymorphisms (SNPs) are related to HCV infection susceptibility and disease progression (Matsuura and Tanaka, 2017). In this setting, Patatin-Like phospholipase domain containing protein 3 (PNPLA3) is involved in lipid storage and its activity has been reported in hydrolysis of triglyceride in the liver (Trepo et al., 2016). The genetic variations of PNPLA3 (rs738409) encoding isoleucine to methionine has been identified to be associated with liver steatosis and fibrosis in patients with HCV infection (Trepo et al., 2016). Moreover, several potent mediators of inflammation are thought to be involved in the process of persistent liver injury and progression of liver fibrosis. In this setting, the polymorphism of cyclooxygenase-2 (COX-2, rs689465) has been linked to pro-inflammatory metabolism, severity of liver fibrosis and HCC development (Miyashita et al., 2012; Bu and Zhao, 2013). In addition, there have increasing data that gene-associated with vitamin D metabolism plays an important role in severity of liver fibrosis (Grunhage et al., 2012). For example, a variant of 7-Dehydrocholesterol reductase (DHCR7) (rs12785878), the rate-limiting enzyme of vitamin D metabolism, is associated with lower vitamin D levels and promotes advance fibrosis in patients with chronic HCV infection (Petta et al., 2013). Previous data of our group have also suggested vitamin D deficiency was common in chronic HCV infection and might be associated with progressive liver fibrosis (Avihingsanon et al., 2014). Thus, the aim of this study was to determine the correlation of PNPLA3 (rs738409), COX-2 (rs689465) and DHCR7 (rs12785878) polymorphisms with severity of liver fibrosis in Thai individuals.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

From 2011 to 2014, 220 patients with chronic HCV mono-infection and 200 patients with HCV/HIV co-infection were enrolled from King Chulalongkorn Memorial Hospital (Bangkok, Thailand) and the HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT, Bangkok, Thailand), respectively. In addition, 200 healthy controls were recruited from The Thai Red Cross Society (Bangkok, Thailand) at the same period. HCV mono-infection was defined by anti-HCV and HCV RNA positive without evidence of HIV infection, while HCV/HIV co-infection was defined by anti-HCV, HCV RNA and anti-HIV positive. Patients with hepatitis B antigen surface antigen (HBsAg) positive or evidence of HCC were excluded.

All participants signed an informed consent before recruited into the study. The research protocol was approved by the Institutional Review Board, Faculty of Medicine, Chulalongkorn University (IRB 412/57 and 583/57).

Genotyping of the SNPs {#sec2-2}
----------------------

Peripheral blood mononuclear cells (PBMCs) were stored at -80 oC until SNP genotyping was performed. Human genomic DNA was extracted and purified by phenol chloroform isoamyl alcohol method. Positive control was obtained from HeLa and HepG2 cell line.

PNPLA3 was performed with the forward primer 5´-TACCACGCCTCTGAAGGAAG-3´, the reverse primer 5´-CCCTGCTCACTTGGAGAAAG-3´ (Falleti et al., 2011) and COX-2 was obtained with the forward primer 5´- GAGCACTACCCATGATAGATGTTAAACA-3´, the reverse primer 5´ - TCTCGTTTTGGAACATAGT TGGATGAG-3´ (Miyashita et al., 2012). PCR amplification was containing 0.5 µM forward and reverse primer, 0.5 µM deoxynucleotidetriphosphate (dNTP), 0.6 units of dreamTaq DNA polymerase (thermo scientific, USA) and 100-500 ng of DNA sample in total volume of 25 µl. PCR condition was consisted with denaturation at 95 oC for 30 s, annealing at 58°C for 30 s and elongation at 72 oC for 30 s in total 40 cycles. Genotyping was verified by TaqMan probe, PNPLA3 rs738409 (Assay ID: C_7241_10), COX-2 rs689465 (Assay ID: C_2517146_10) and DHCR7 rs12785878 (Assay ID: C_32063037_10) that classified genotype by allelic discrimination method (Applied Biosystems, Foster City, CA) (Zhang et al., 2012). PCR reaction for genotyping was performed with Perfect Taq Master Mix (5 PRIME, Darmstadt, Germany) in total volume of 10 µl as recommended by the manufacturer's instruction. The PCR conditions were followed by holding stage at 95°C for 10 min, denaturation at 92°C for 15 s and annealing/extension at 60°C for 1 min in total 40 cycles. The fluorescence signals (VIC and FAM) that specific to each SNPs were detected and reported by the ABI Step One Plus real-time PCR system (Applied Biosystems).

Liver stiffness measurement {#sec2-3}
---------------------------

Liver stiffness measurement (LSM) was obtained from each patient with HCV mono-infection and HCV/HIV co-infection after fasting for at least 2 hours by transient elastography (FibroScan, Echosens, Paris, France). Results were recorded in kilopascals (kPa) as the median value of all measurements. The procedure was based on at least 10 validated measurements: the success rate (ratio between numbers of validated and total measurements) was over 60% and interquartile range was less than 30% (Castera et al., 2012). Liver fibrosis stages were defined according to LSM: F0-F1 (\<7.1 kPa), F2 (7.1-9.4 kPa), F3 (9.5-14.0) and F4 (\>14.0 kPa) (Avihingsanon et al., 2014).

Statistical analysis {#sec2-4}
--------------------

Genotyping of the SNPs was reported in allelic discrimination plot. Data were presented as Mean ± standard deviation (SD) and categorical variables as frequency and percentage as appropriate. Frequencies (%) of genotype distribution in study population data were compared to the control groups using online GraphPad Software (<http://www.graphpad.com>). Moreover, the correlation of the studied SNPs with advanced liver fibrosis was calculated by using a binary variable and the univariate odds ratios (OR) in MedCal Software (<http://www.medcalc.org>). The results were considered as significant when P\<0.05 (two-tailed) and frequencies by chi-square test using SPSS software version 22.0.

Results {#sec1-3}
=======

Baseline characteristics of the participants {#sec2-5}
--------------------------------------------

The characteristics of all participants are shown in [Table 1](#T1){ref-type="table"}. The mean age of the healthy control group was significantly higher compared with the other groups (P\<0.001). However, there was no significant difference in mean age among the HCV mono-infected and HCV/HIV co-infected groups. HCV/HIV co-infected patients had higher proportion of male gender compared the other groups (P\<0.001). In addition, HCV/HIV co-infected patients had significantly higher mean LSM compared with HCV mono-infected patients (P\<0.001). There was no difference between HCV mono-infected and HCV/HIV co-infected patients in terms of serum alanine aminotransferase (ALT), HCV RNA levels and HCV genotype distribution.

###### 

Baseline Characteristics of the Participants in This Study

                            HCV mono-infection (n=220)   HCV/HIV co-infection (n= 200)   Healthy control (n=200)   P
  ------------------------- ---------------------------- ------------------------------- ------------------------- ---------
  Age (years)               43.1±10.4                    42.6±7.2                        47.5±5.2                  \<0.001
  Gender                                                                                                           
   Male (%)                 155 (70.5%)                  179 (89.5%)                     111 (55.5%)               \<0.001
   Female (%)               65 (29.5%)                   21 (10.5%)                      89 (44.5%)                
  ALT (IU/L)                71.5± 57.4                   75.4± 61.3                      ND                        0.872
  HCV-RNA (log~10~ IU/ml)   6.2± 2.1                     6.3± 1.9                        ND                        0.554
  HCV genotypes                                                                          ND                        0.372
   1                        75 (34.1%)                   76 (38.0%)                                                
   3                        105 (47.7%)                  80 (40.0%)                                                
   6                        40 (18.2%)                   30 (15.0%)                                                
   Unknown                  0(0%)                        14 (7.0%)                                                 
  Fibrosis stage                                                                         ND                        \<0.001
   F0-F1/F2                 150 (68.2%)                  97 (48.5%)                                                
   F3/F4                    70 (31.8%)                   103 (51.5%)                                               
  Liver stiffness (kPa)     10.2±8.6                     13.3±10.5                       ND                        0.001

HCV, Hepatitis C virus; HIV, Human immunodeficiency virus; ND, No data; Fibrosis stage cutoff; F0-F1 (\<7.1 kPa), F2 (7.1-9.4 kPa), F3 (9.5-14.0) and F4 (\>14.0 kPa).

PNPLA3 rs738409 genotype distribution {#sec2-6}
-------------------------------------

The genotype frequencies of PNPLA3 (rs738409) did not deviate from Hardy-Weinberg Equilibrium in all the studied participants. The genotype distributions and allele frequencies of the SNP are presented in [Table 2](#T2){ref-type="table"}. The frequencies of CC, CG and GG genotypes in HCV mono-infected patients were 53.2%, 40.3% and 6.5%, respectively, while the corresponding genotypes were 50.8%, 39.2%, and 10.0% in the HCV/HIV co-infected patients. Moreover, the corresponding genotype frequencies were 45.5%, 44.0% and 10.5% in the healthy controls. Compared with the healthy control group, HCV mono-infected patients had lower distribution of G allele \[odds ratio (OR) =0.73, 95% confidence interval (CI) =0.55-0.99, P=0.043\]. However, the genotype and allele frequencies were similar between controls and patients with HCV/HIV co-infection. In addition, the genotype distributions and allele frequencies were not different between the HCV mono-infected and HCV/HIV co-infected groups.

###### 

Genotype and Allele Frequencies of the Studied SNPs in Patients with HCV Infection and Controls

  SNPs              HCV (n=220)   HCV-HIV (n=200)   Control (n=200)   HCV vs. control    HCV-HIV vs. control   HCV-HIV vs. HCV                                    
  ----------------- ------------- ----------------- ----------------- ------------------ --------------------- ------------------ ----------- ------------------- -------
  *PNPLA3*                                                                                                                                                        
  Allelic model                                                                                                                                                   
   Major (C)        325           282               270               1                                        1                              1                   
   Minor (G)        115           118               130               0.73 (0.55-0.99)   0.043\*               0.87 (0.64-1.17)   0.359       1.18 (0.87-1.60)    0.277
  Additive model                                                                                                                                                  
   CC               120           102               91                1                                        1                              1                   
   CG               85            78                88                0.73 (0.49-1.10)   0.131                 0.79 (0.52-1.20)   0.268       1.08 (0.72-1.62)    0.711
   GG               15            20                21                0.54 (0.26-1.11)   0.094                 0.85 (0.43-1.67)   0.636       1.57 (0.76-3.22)    0.22
  Dominant model                                                                                                                                                  
   CC               120           102               91                1                                        1                              1                   
   CG+GG            100           98                109               0.70 (0.47-1.02)   0.064                 0.80 (0.54-1.19)   0.271       1.15 (0.79-1.69)    0.467
  Recessive model                                                                                                                                                 
   CC+CG            205           180               179               1                                        1                              1                   
   GG               15            20                21                0.62 (0.31-1.25)   0.181                 0.95 (0.50-1.81)   0.869       1.52 (0.755-3.05)   0.241
  *COX-2*                                                                                                                                                         
  Allelic model                                                                                                                                                   
   Major (A)        387           346               295               1                                        1                              1                   
   Minor (G)        53            54                105               0.38 (0.27-0.55)   \<0.001\*             0.44 (0.31-0.63)   \<0.001\*   1.14 (0.76-1.71)    0.528
  Additive model                                                                                                                                                  
   AA               172           152               115               1                                        1                              1                   
   AG               43            42                65                0.44 (0.28-0.70)   \<0.001\*             0.49 (0.31-0.77)   0.002\*     1.11 (0.69-1.78)    0.682
   GG               5             6                 20                0.17 (0.06-0.46)   \<0.001\*             0.23 (0.09-0.58)   0.002\*     1.36 (0.41-4.54)    0.619
  Dominant model                                                                                                                                                  
   AA               172           152               115               1                                        1                              1                   
   AG+GG            48            48                85                0.38 (0.25-0.58)   \<0.001\*             0.43 (0.28-0.66)   \<0.001\*   1.13 (0.72-1.78)    0.595
  Recessive model                                                                                                                                                 
   AA+AG            215           194               180               1                                        1                              1                   
   GG               5             6                 20                0.21 (0.08-0.57)   0.002\*               0.28 (0.11-0.71)   0.007\*     1.33 (0.40-4.43)    0.642
  *DHCR7*                                                                                                                                                         
  Allelic model                                                                                                                                                   
   Major (T)        334           307               268               1                                        1                              1                   
   Minor (G)        106           93                132               0.64 (0.48-0.87)   0.004\*               0.62 (0.45-0.84)   0.002\*     0.96 (0.69-1.31)    0.774
  Additive model                                                                                                                                                  
   TT               125           114               92                1                                        1                              1                   
   TG               84            79                84                0.74 (0.49-1.10)   0.138                 0.76 (0.50-1.15)   0.19        1.03 (0.69-1.54)    0.88
   GG               11            7                 24                0.34 (0.16-0.72)   0.005\*               0.24 (0.10-0.57)   0.001\*     0.70 (0.26-1.86)    0.472
  Dominant model                                                                                                                                                  
   TT               125           114               92                1                                        1                              1                   
   TG+GG            95            86                108               0.65 (0.44-0.95)   0.027\*               0.64 (0.43-0.95)   0.028\*     0.99 (0.67-1.46)    0.97
  Recessive model                                                                                                                                                 
   TT+TG            209           193               176               1                                        1                              1                   
   GG               11            7                 24                0.39 (0.18-0.81)   0.012\*               0.27 (0.11-0.63)   0.003\*     0.69 (0.26-1.81)    0.451

OR, odd ratio; CI, confidence interval

COX-2 rs689465 genotype distribution {#sec2-7}
------------------------------------

The genotype distributions and allele frequencies of COX-2 (rs689465) are shown in [Table 2](#T2){ref-type="table"}. In the HCV mono-infected group, the frequencies of AA, AG and GG genotypes were 78.2%, 19.5% and 2.3%, respectively. The corresponding genotypes was 76.0%, 21.0% and 3.0% in the HCV/HIV co-infection group, while their distribution in the healthy control group were 57.5%, 32.5% and 10.0%, respectively. Our results showed that the frequencies of AG and GG genotypes were less common in the HCV mono-infection group compare with healthy controls (OR=0.44, 95%CI=0.28-0.71; P\<0.001 and OR=0.17, 95%CI=0.06-0.46; P\<0.001, respectively). Similar results were found among HCV/HIV co-infected patients compared with the healthy controls regarding the distribution of AG and GG genotypes (OR=0.49, 95%CI=0.31-0.77; P=0.002 and OR= 0.23, 95%CI=0.09-0.58; P=0.002, respectively). However, the genotype distributions and allele frequencies were not different between the HCV mono-infected and HCV/HIV co-infected groups ([Table 2](#T2){ref-type="table"}).

DHCR7 rs12785878 genotype distribution {#sec2-8}
--------------------------------------

The frequency of TT, TG and GG genotypes of DHCR7 (rs12785878) in each group are shown in [Table 2](#T2){ref-type="table"}. In the HCV mono-infected group, their frequencies were 56.8%, 38.2% and 5.0%, respectively, while their distribution in the HCV/HIV co-infected group were 67.0%, 39.5% and 3.5%, respectively. The corresponding genotypes in the healthy control group were 46.0%, 42.0% and 12.0%, respectively. The GG genotype was less frequently distributed in the HCV mono-infected group than in the healthy control group (OR=0.34, 95% CI=0.16-0.72, P=0.005). Likewise, GG genotype was less common in the HCV/HIV co-infected group than the healthy control group (OR=0.24, 95%CI=0.10-0.57, P=0.0001). However, the genotype distributions and allele frequencies were not different between the HCV mono-infected and HCV/HIV co-infected groups ([Table 2](#T2){ref-type="table"}).

Independent and additive effects of the SNPs associated with advanced liver fibrosis {#sec2-9}
------------------------------------------------------------------------------------

To identify factors associated advanced liver fibrosis (F3 and F4, LSM≥9.5 kPa), baseline characteristics including patient's age, gender, ALT, HIV co-infection, HCV RNA viral load, HCV genotype, SNPs rs738409, rs689465 and rs12785878 were evaluated by logistic regression analyses. The data showed that age, HIV co-infection, SNPs rs738409 and rs689465 were associated with advanced liver fibrosis in univariate and multivariate analyses ([Table 3](#T3){ref-type="table"}).

###### 

Univariate and Multivariate Regression Analyses of Factors Associated with Advanced Liver Fibrosis (LSM ≥ 9.5 kPa)

  Factors                  Category           Univariate analysis   Multivariate analysis                      
  ------------------------ ------------------ --------------------- ----------------------- ------------------ -----------
  Baseline                                                                                                     
   Age (years)             \< 40 vs. ≥ 40     4.08 (2.65-6.27)      \<0.001\*               4.44 (2.82-6.98)   \<0.001\*
   Sex                     Male vs. Female    1.59 (0.96-2.62)      0.07                                       
   ALT (U/L)               \< 75 vs. ≥ 75     0.98 (0.42-2.30)      0.965                                      
   HIV co-infection        yes vs. no         2.28 (1.53-3.38)      \<0.001\*               2.39 (1.56-3.67)   \<0.001\*
   Log10 HCV RNA (IU/mL)   \< 6.0 vs. ≥ 6.0   1.10 (0.57-2.15)      0.81                                       
   HCV genotypes           1 vs. 3 and 6      1.01 (0.82-1.24)      0.92                                       
  SNPs                                                                                                         
   *PNPLA3* (rs738409)     GG vs. non-GG      1.42 (1.01-2.02)      0.049\*                 1.48 (1.01-2.16)   0.045\*
   *COX-2* (rs689465)      GG vs. non-GG      2.59 (1.20-5.61)      0.016\*                 2.63 (1.19-5.80)   0.017\*
   *DHCR7* (rs12785878)    GG vs. non-GG      0.84 (0.51-1.38)      0.491                                      

ALT, alanine aminotransferase; SNPs, Single nucleotide polymorphisms; CI, confidence interval

The combined effect of the risk genotypes, including rs738409 (CG+GG) and rs689465 AG+GG) on the presence of advanced liver fibrosis were further investigated. Among patients with advanced liver fibrosis, there were 66 (39.1%) patients who did not carry any risk genotype, while there were 67 (37.6%), 31 (53.4%) and 9 (60.0%) patients who had 1, 2 and 3 risk genotypes, respectively (P=0.044, Chi-square test for trend analysis). These data showed that the percentage of patients with advanced liver fibrosis increased significantly along with the accumulated numbers of the risk genotypes.

Discussion {#sec1-4}
==========

Natural history and clinical outcome of HCV infection display remarkably inter-individual differences. Previous data have shown that more than 70% of acute HCV infection progress to chronic infection, in which approximately 20% of cases will develop towards cirrhosis and finally HCC (Lemoine and Thursz, 2014). Increasing data have indicated that the clinical course and disease progression of HCV infection is related to interaction of various factors including viral, host and environmental factors (Matsuura and Tanaka, 2017). Regarding host genetic variations, previous genome-wide association studies (GWAS) have shown that SNPs near the interferon lambda-3 (IFNL3) and interferon lambda-4 (IFNL4) genes are predictors of spontaneous HCV clearance and response to pegylated interferon-based therapy (Tanaka et al., 2009; Prokunina-Olsson et al., 2013). Recent GWAS have also identified additional genetic variations associated with the severity of liver fibrosis and HCC development (Matsuura et al., 2017).

In this report, multivariate analysis showed that PNPLA3 GG genotype was an independent risk factor associated with advanced liver fibrosis assessed by LSM. Indeed, LSM with transient elastography appears to be a reliable non-invasive tool to detect significant fibrosis or cirrhosis in patients with chronic HCV infection (Houot et al., 2016). Our results are in agreement with previous reports demonstrating that PNPLA3 polymorphism influenced the progression of liver fibrosis in HCV mono-infected and HCV/HIV co-infected patients (Trepo et al., 2011; Ali et al., 2016; Jimenez-Sousa et al., 2016; Nunez-Torres et al., 2016). For instance, an analysis of data from participants in a large cohort of HCV mono-infection showed that PNPLA3 genotype was significantly associated with the presence of cirrhosis after adjusting for other factors (Ali et al., 2016). In addition, a recent study reported that the presence of PNPLA3 (rs738409) G allele increased the odds of having advanced liver fibrosis in HCV/HIV co-infected patients (Jimenez-Sousa et al., 2016). In contrast, an association between the PNPLA3 polymorphism and the degree of liver fibrosis was not confirmed in other reports of HCV mono- and co-infection (Nakamura et al., 2013; Sagnelli et al., 2016).

COX-2 represents an inducible enzyme that converts arachidonic acid to prostaglandins, which are potent mediators of inflammation involved in several cellular processes including proliferation, carcinogenesis and metastasis (Simmons et al., 2004). Our data showed that COX-2 (rs689465) GG genotype was identified as a predictor of advanced liver fibrosis by multivariate analysis. This result was in accordance with a Japanese study demonstrating that rs689465 polymorphism was linked to liver disease progression in patients with HCV mono-infection (Miyashita et al., 2012). Moreover, a recent meta-analysis have suggested that COX-2 (rs689465) variant might be a factor associated with HCC risk in Asian populations (Bu and Zhao, 2013). Interestingly, our data also show for the first that the combined testing of PNPLA3 (rs738409) and COX-2 (rs689465) could exhibit an additive effect towards the presence of advanced liver fibrosis. Taken together, these results indicate that PNPLA3 and COX-2 variants might play a significant role in the progression of liver fibrosis in HCV mono-infected and HCV/HIV co-infected patients.

The mechanism underlying this association remains unclear as PNPLA3 does not seem to have a direct impact on the natural history of chronic HCV infection. In fact, rs738409 GG allele might not directly affect the PNPLA3 mRNA levels but it could result in an inhibition of PNPLA3 function and influence towards susceptibility to intrahepatic fat accumulation. As a result, it could be explained that PNPLA3 variant promotes liver fat accumulation, which in turn leads to progressive steatosis and, ultimately, the development of liver fibrosis and cirrhosis (Trepo et al., 2011). Regarding the role of COX-2, previous data suggested that patients with risk allele of rs689465 had higher expression levels of COX-2 mRNA in the liver and lymphoid cells (Miyashita et al., 2012). It was also showed that COX-2 over-expression in the hepatocytes was associated with advanced liver fibrosis in patients with chronic HCV infection (Nunez et al., 2004). Thus, it is speculated that COX-2 GG genotype might promote higher levels of COX-2 expression, resulting greater liver inflammation and progressive liver fibrosis.

It has been recently showed that vitamin D, a potent immune-modulator, is associated with the pathogenesis of various disorders, including chronic HCV infection (Grunhage et al., 2012). In fact, hypovitaminosis D is frequently found among patients with chronic HCV infection. In our previous report, vitamin D insufficiency and deficiency were found in more than 60% of patients with HCV mono- and co-infection (Avihingsanon et al., 2014). In addition, common SNPs in vitamin D-related genes, such as DHCR7, CYP27B1, vitamin D receptor (VDR) and vitamin D binding protein (DBP), are linked to clinical manifestation and treatment response in patients with chronic HCV infection (Grunhage et al., 2012). For instance, a recent Italian report found an association between severity of liver fibrosis and DHCR7 variant in patients with HCV genotype 1 infection (Petta et al., 2013). In contrast, our cohort did not show that DHCR7 genotypes influenced progressive liver fibrosis in patients with chronic HCV infection. This discrepancy between studies might be related to the heterogeneity of reports in terms of studied population, genetic background, sample size, HCV genotypes, and differences in methods of liver fibrosis assessment. In light of this inconsistency, the roles of vitamin D-related SNPs in the clinical outcome of chronic HCV infection need to be elucidated in further studies.

In conclusion, PNPLA3 (rs738409) and COX-2 (rs689465) polymorphisms were associated with advanced liver fibrosis, suggesting that these variants might play an important role in liver fibrogenesis in patients with HCV mono- and co-infection. Given a higher chance for developing advanced fibrosis/cirrhosis and subsequent complications, patients harboring these risk genotypes may warrant closely monitored the clinical progression and being prioritized for antiviral therapy. Further cohorts with larger sample sizes should be performed to confirm these observations.
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